{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:59:49Z","timestamp":1793361589782,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical University of Silesia in Katowice","award":["PCN-2-036\/N\/0\/O"],"award-info":[{"award-number":["PCN-2-036\/N\/0\/O"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The patients were divided into four sex-matched groups: group C (<jats:italic>n<\/jats:italic>\u2009=\u200925) \u2013 control group \u2013 subjects who did not use topical antiglaucoma medications, group DL (<jats:italic>n<\/jats:italic>\u2009=\u200914) \u2013 patients using preservative-free dorzolamide, group DL\u2009+\u2009BAC (<jats:italic>n<\/jats:italic>\u2009=\u200916) \u2013 patients using topical BAC-preserved dorzolamide, group BL\u2009+\u2009BAC (<jats:italic>n<\/jats:italic>\u2009=\u200917) \u2013 patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6\u201312 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL\u2009+\u2009BAC and BL\u2009+\u2009BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL\u2009+\u2009BAC and BL\u2009+\u2009BAC when compared to group C. Oxidative Stress Index was higher in the groups DL\u2009+\u2009BAC and BL\u2009+\u2009BAC in comparison with the groups DL and C.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-021-02079-y","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:02:56Z","timestamp":1630519376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film"],"prefix":"10.1186","volume":"21","author":[{"given":"Lech","family":"Sedlak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"\u015awierczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Borymska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Wygl\u0119dowska-Promie\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"2079_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.phrs.2012.03.002","volume":"66","author":"A Pascale","year":"2012","unstructured":"Pascale A, Drago F, Govoni S. Protecting the retinal neurons from glaucoma: lowering ocular pressure is not enough. Pharmacol Res. 2012;66:19\u201332. https:\/\/doi.org\/10.1016\/j.phrs.2012.03.002.","journal-title":"Pharmacol Res"},{"key":"2079_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OPTH.S229815","volume":"14","author":"AL Mylla Boso","year":"2020","unstructured":"Mylla Boso AL, Gasperi E, Fernandes L, et al. Impact of Ocular Surface Disease Treatment in Patients with Glaucoma. Clin Ophthalmol. 2020;14:103\u201311. https:\/\/doi.org\/10.2147\/OPTH.S229815.","journal-title":"Clin Ophthalmol"},{"key":"2079_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"EW Leung","year":"2008","unstructured":"Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350\u20135. https:\/\/doi.org\/10.1097\/IJG.0b013e31815c5f4f.","journal-title":"J Glaucoma"},{"key":"2079_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312\u201334. https:\/\/doi.org\/10.1016\/j.preteyeres.2010.03.001.","journal-title":"Prog. Retin. Eye Res"},{"key":"2079_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/17469899.4.1.59","volume":"4","author":"PD Freeman","year":"2009","unstructured":"Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol. 2009;4:59\u201364. https:\/\/doi.org\/10.1586\/17469899.4.1.59.","journal-title":"Expert Rev Ophthalmol"},{"key":"2079_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/01.ico.0000183538.53017.69","volume":"25","author":"C Charnock","year":"2006","unstructured":"Charnock C. Are multidose over-the-counter artificial tears adequately preserved? Cornea. 2006;25:432\u20137. https:\/\/doi.org\/10.1097\/01.ico.0000183538.53017.69.","journal-title":"Cornea"},{"key":"2079_CR7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2147\/OPTH.S211611","volume":"13","author":"K Walsh","year":"2019","unstructured":"Walsh K, Jones L. The use of preservatives in dry eye drops. Clin Ophthalmol. 2019;13:1409\u201325. https:\/\/doi.org\/10.2147\/OPTH.S211611.","journal-title":"Clin Ophthalmol"},{"key":"2079_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","volume":"15","author":"JAP Gomes","year":"2017","unstructured":"Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15:511\u201338. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.004.","journal-title":"Ocul Surf"},{"key":"2079_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.aanat.2018.12.003","volume":"222","author":"A Rath","year":"2019","unstructured":"Rath A, Eichhorn M, Tr\u00e4ger K, et al. In vitro effects of benzalkonium chloride and prostaglandins on human meibomian gland epithelial cells. Ann Anat. 2019;222:129\u201338. https:\/\/doi.org\/10.1016\/j.aanat.2018.12.003.","journal-title":"Ann Anat"},{"key":"2079_CR10","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1167\/iovs.14-14548","volume":"55","author":"S Barabino","year":"2014","unstructured":"Barabino S, Antonelli S, Cimbolini N, et al. The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye. Invest Ophthalmol Vis Sci. 2014;55:6499\u2013504. https:\/\/doi.org\/10.1167\/iovs.14-14548.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2079_CR11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/bjophthalmol-2017-311544","volume":"102","author":"DW Steven","year":"2018","unstructured":"Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018;102:1497\u2013503. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311544.","journal-title":"Br J Ophthalmol"},{"key":"2079_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1080\/17425255.2016.1209481","volume":"12","author":"AA Bonniard","year":"2016","unstructured":"Bonniard AA, Yeung JY, Chan CC, et al. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12:1279\u201389. https:\/\/doi.org\/10.1080\/17425255.2016.1209481.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2079_CR13","doi-asserted-by":"publisher","first-page":"e26103","DOI":"10.1371\/journal.pone.0026103","volume":"6","author":"W Chen","year":"2011","unstructured":"Chen W, Li Z, Hu J, et al. Corneal alternations induced by topical application of benzalkonium chloride in rabbit. PLoS One. 2011;6:e26103. https:\/\/doi.org\/10.1371\/journal.pone.0026103.","journal-title":"PLoS One"},{"key":"2079_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/112067210801800314","volume":"18","author":"M Ciancaglini","year":"2008","unstructured":"Ciancaglini M, Carpineto P, Agnifili L, et al. An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes. Eur J Ophthalmol. 2008;18:400\u20137. https:\/\/doi.org\/10.1177\/112067210801800314.","journal-title":"Eur J Ophthalmol"},{"key":"2079_CR15","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1167\/iovs.12-10766","volume":"53","author":"A Pauly","year":"2012","unstructured":"Pauly A, Roubeix C, Liang H, et al. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci. 2012;53:8172\u201380. https:\/\/doi.org\/10.1167\/iovs.12-10766.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2079_CR16","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1167\/iovs.11-8775","volume":"53","author":"J Sarkar","year":"2012","unstructured":"Sarkar J, Chaudhary S, Namavari A, et al. Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci. 2012;53:1792\u2013802. https:\/\/doi.org\/10.1167\/iovs.11-8775.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2079_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s00417-006-0353-z","volume":"245","author":"A Pauly","year":"2007","unstructured":"Pauly A, Brignole-Baudouin F, Guenoun JM, et al. Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles. Graefes Arch Clin Exp Ophthalmol. 2007;245:534\u201346. https:\/\/doi.org\/10.1007\/s00417-006-0353-z.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2079_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/09273941003721926","volume":"18","author":"M Calonge","year":"2010","unstructured":"Calonge M, Enr\u00edquez-de-Salamanca A, Diebold Y, et al. Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm. 2010;18:244\u201353. https:\/\/doi.org\/10.3109\/09273941003721926.","journal-title":"Ocul Immunol Inflamm"},{"key":"2079_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.tiv.2017.02.006","volume":"41","author":"M Bouchemi","year":"2017","unstructured":"Bouchemi M, Roubeix C, Kessal K, et al. Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma. Toxicol In Vitro. 2017;41:21\u20139. https:\/\/doi.org\/10.1016\/j.tiv.2017.02.006.","journal-title":"Toxicol In Vitro"},{"key":"2079_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/112067210701700311","volume":"17","author":"N Jaenen","year":"2007","unstructured":"Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341\u20139. https:\/\/doi.org\/10.1177\/112067210701700311.","journal-title":"Eur J Ophthalmol"},{"key":"2079_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418\u201323. https:\/\/doi.org\/10.1136\/bjo.86.4.418.","journal-title":"Br J Ophthalmol"},{"key":"2079_CR22","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1042\/BCJ20160115","volume":"473","author":"CT Supuran","year":"2016","unstructured":"Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473:2023\u201332. https:\/\/doi.org\/10.1042\/BCJ20160115.","journal-title":"Biochem J"},{"key":"2079_CR23","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.2147\/OPTH.S33254","volume":"6","author":"GA Auger","year":"2012","unstructured":"Auger GA, Raynor M, Longstaff S. Patient perspectives when switching from Cosopt(\u00ae) (dorzolamide-timolol) to AzargaTM (brinzolamide-timolol) for glaucoma requiring multiple drug therapy. Clin Ophthalmol. 2012;6:2059\u201362. https:\/\/doi.org\/10.2147\/OPTH.S33254.","journal-title":"Clin Ophthalmol"},{"key":"2079_CR24","first-page":"529","volume":"23","author":"AF Ablamowicz","year":"2017","unstructured":"Ablamowicz AF, Nichols JJ. Concentrations of MUC16 and MUC5AC using three tear collection methods. Mol Vis. 2017;23:529\u201337.","journal-title":"Mol Vis"},{"key":"2079_CR25","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ki.1996.186","volume":"49","author":"V Witko-Sarsat","year":"1996","unstructured":"Witko-Sarsat V, Friedlander M, Capeill\u00e8re-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304\u201313. https:\/\/doi.org\/10.1038\/ki.1996.186.","journal-title":"Kidney Int"},{"key":"2079_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","volume":"82","author":"GL Ellman","year":"1959","unstructured":"Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70\u20137. https:\/\/doi.org\/10.1016\/0003-9861(59)90090-6.","journal-title":"Arch Biochem Biophys"},{"key":"2079_CR27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.clinbiochem.2005.08.008","volume":"38","author":"O Erel","year":"2005","unstructured":"Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103\u201311. https:\/\/doi.org\/10.1016\/j.clinbiochem.2005.08.008.","journal-title":"Clin Biochem"},{"key":"2079_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.clinbiochem.2003.10.014","volume":"37","author":"O Erel","year":"2004","unstructured":"Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:12\u20139. https:\/\/doi.org\/10.1016\/j.clinbiochem.2003.10.014.","journal-title":"Clin Biochem"},{"key":"2079_CR29","doi-asserted-by":"publisher","first-page":"e0126561","DOI":"10.1371\/journal.pone.0126561","volume":"10","author":"R Deng","year":"2015","unstructured":"Deng R, Hua X, Li J, et al. Oxidative stress markers induced by hyperosmolarity in primary human corneal epithelial cells. PLoS One. 2015;10:e0126561. https:\/\/doi.org\/10.1371\/journal.pone.0126561.","journal-title":"PLoS One"},{"key":"2079_CR30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/ceo.13814","volume":"48","author":"I Mohammed","year":"2020","unstructured":"Mohammed I, Kulkarni B, Faraj LA, et al. Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study. Clin Exp Ophthalmol. 2020;48:973\u201382. https:\/\/doi.org\/10.1111\/ceo.13814.","journal-title":"Clin Exp Ophthalmol"},{"key":"2079_CR31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1167\/iovs.03-1067","volume":"45","author":"PJ Pisella","year":"2004","unstructured":"Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360\u20138. https:\/\/doi.org\/10.1167\/iovs.03-1067.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2079_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2147\/OPTH.S91402","volume":"10","author":"H Uusitalo","year":"2016","unstructured":"Uusitalo H, Egorov E, Kaarniranta K, et al. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445\u201354. https:\/\/doi.org\/10.2147\/OPTH.S91402.","journal-title":"Clin Ophthalmol"},{"key":"2079_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.22336\/rjo.2019.38","volume":"63","author":"S Kumar","year":"2019","unstructured":"Kumar S, Singh T, Ichhpujani P, et al. Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost. Rom J Ophthalmol. 2019;63:249\u201356.","journal-title":"Rom J Ophthalmol"},{"key":"2079_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1089\/jop.2013.0216","volume":"30","author":"M Iester","year":"2014","unstructured":"Iester M, Telani S, Frezzotti P, et al. Beta-Blocker Study Group et al. Beta-Blocker Study Group. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers. J Ocul Pharmacol Ther. 2014;30:476\u201381. https:\/\/doi.org\/10.1089\/jop.2013.0216.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2079_CR35","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00417-010-1397-7","volume":"248","author":"A Shedden","year":"2010","unstructured":"Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide\/timolol fixed combination (COSOPTTM) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010;248:1757\u201364. https:\/\/doi.org\/10.1007\/s00417-010-1397-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2079_CR36","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1111\/aos.13526","volume":"96","author":"S Seen","year":"2018","unstructured":"Seen S, Tong L. Dry eye disease and oxidative stress. Acta Ophthalmol. 2018;96:e412\u2013e420. https:\/\/doi.org\/10.1111\/aos.13526.","journal-title":"Acta Ophthalmol"},{"key":"2079_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2147\/cia.s52662","volume":"9","author":"MD Pinazo-Dur\u00e1n","year":"2014","unstructured":"Pinazo-Dur\u00e1n MD, Gallego-Pinazo R, Garc\u00eda-Medina JJ, et al. Oxidative stress and its downstream signaling in aging eyes. Clin Interv Aging. 2014;9:637\u201352. https:\/\/doi.org\/10.2147\/cia.s52662.","journal-title":"Clin Interv Aging."},{"key":"2079_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.exer.2006.10.008","volume":"84","author":"SC Sacc\u00e0","year":"2007","unstructured":"Sacc\u00e0 SC, Izzotti A, Rossi P, et al. Glaucomatous outflow pathway and oxidative stress. Exp Eye Res. 2007;84:389\u201399. https:\/\/doi.org\/10.1016\/j.exer.2006.10.008.","journal-title":"Exp Eye Res"},{"key":"2079_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/ICO.0b013e31826a5de1","volume":"31","author":"Y Uchino","year":"2012","unstructured":"Uchino Y, Kawakita T, Ishii T, et al. A new mouse model of dry eye disease: oxidative stress affects functional decline in the lacrimal gland. Cornea. 2012;31:63\u20137. https:\/\/doi.org\/10.1097\/ICO.0b013e31826a5de1.","journal-title":"Cornea"},{"key":"2079_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cca.2005.12.035","volume":"369","author":"Y Ohashi","year":"2006","unstructured":"Ohashi Y, Dogru M, Tsubota K. Laboratory findings in tear fluid analysis. Clin Chim Acta. 2006;369:17\u201328. https:\/\/doi.org\/10.1016\/j.cca.2005.12.035.","journal-title":"Clin Chim Acta"},{"key":"2079_CR41","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s1542-0124(12)70185-4","volume":"7","author":"Y Chen","year":"2009","unstructured":"Chen Y, Mehta G, Vasiliou V. Antioxidant defenses in the ocular surface. Ocul Surf. 2009;7:176\u201385. https:\/\/doi.org\/10.1016\/s1542-0124(12)70185-4.","journal-title":"Ocul Surf"},{"key":"2079_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajme.2017.09.001","volume":"54","author":"OM Ighodaro","year":"2018","unstructured":"Ighodaro OM, Akinloye OA. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alexandria Journal of Medicine. 2018;54:287\u201393. https:\/\/doi.org\/10.1016\/j.ajme.2017.09.001.","journal-title":"Alexandria Journal of Medicine"},{"key":"2079_CR43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/02713680801971857","volume":"33","author":"E Brasnu","year":"2008","unstructured":"Brasnu E, Brignole-Baudouin F, Riancho L, et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33:303\u201312. https:\/\/doi.org\/10.1080\/02713680801971857.","journal-title":"Curr Eye Res"},{"key":"2079_CR44","first-page":"3364","volume":"17","author":"H Wu","year":"2011","unstructured":"Wu H, Zhang H, Wang C, et al. Genoprotective effect of hyaluronic acid against benzalkonium chloride-induced DNA damage in human corneal epithelial cells. Mol Vis. 2011;17:3364\u201370.","journal-title":"Mol Vis"},{"key":"2079_CR45","first-page":"40","volume":"110","author":"C Baudouin","year":"2012","unstructured":"Baudouin C, Denoyer A, Desbenoit N, et al. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2012;110:40\u201363.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2079_CR46","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/medicina55070366","volume":"55","author":"L Sedlak","year":"2019","unstructured":"Sedlak L, Zych M, Wojnar W, et al. Effect of Topical Prostaglandin F2\u03b1 Analogs on Selected Oxidative Stress Parameters in the Tear Film. Medicina (Kaunas). 2019;55:366. https:\/\/doi.org\/10.3390\/medicina55070366.","journal-title":"Medicina (Kaunas)"},{"key":"2079_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/15569527.2020.1787435","volume":"39","author":"L Sedlak","year":"2020","unstructured":"Sedlak L, Wojnar W, Zych M, et al. Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film. Cutan Ocul Toxicol. 2020;39:260\u20138. https:\/\/doi.org\/10.1080\/15569527.2020.1787435.","journal-title":"Cutan Ocul Toxicol"},{"key":"2079_CR48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3109\/10715762.2015.1110241","volume":"50","author":"MA Comini","year":"2016","unstructured":"Comini MA. Measurement and meaning of cellular thiol:disufhide redox status. Free Radic Res. 2016;50:246\u201371. https:\/\/doi.org\/10.3109\/10715762.2015.1110241.","journal-title":"Free Radic Res"},{"key":"2079_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2008.08.006","volume":"30","author":"HJ Forman","year":"2009","unstructured":"Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30:1\u201312. https:\/\/doi.org\/10.1016\/j.mam.2008.08.006.","journal-title":"Mol Aspects Med."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02079-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-021-02079-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02079-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:05:09Z","timestamp":1630519509000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-02079-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2079"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-02079-y","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Bioethical Committee of Medical University of Silesia (approval number: KNW\/0022\/KB1\/87\/17). All procedures were performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial or non-financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"319"}}